Pharmaceutical Technology

MAY 24, 2023

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Pharmaceutical Technology

MARCH 20, 2023

These high rates of diseases in largely untapped patient pools, present invaluable opportunities to trial new drugs that can help people living with chronic conditions and battling serious illnesses. However, Africa currently accounts for a very low percentage of global clinical trials, with estimates putting it at approximately 2.5%.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Clinical Supply Chain 130

Drug Discovery World

MARCH 13, 2023

Repercussions of the Covid-19 pandemic The idea that the Covid-19 pandemic dramatically affected the CGT supply chain and upturned CGT manufacturing has dominated the conversation in the biotech sector 3. But now, the increased efficiency is likely making drug development cheaper. So what bottlenecks are making CGT so inaccessible?

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

The Pharma Data

AUGUST 15, 2021

Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease. About VTX-801.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

XTalks

APRIL 11, 2024

After backing from the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) last month, Johnson and Johnson (J&J) and Bristol Myers Squibb (BMS) scored FDA approvals for the use of their B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies as earlier line treatment options for multiple myeloma.

FDA Approval 52

FDA Approval Manufacturing Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 3, 2022

Paul Viggers , Chief Commercial Officer at TrakCel, explains how it fits into the drug discovery and development sector. . 1 Emily was a seven-year-old girl who relapsed a second time following two years battling leukaemia, out of standard treatment options, and her life was saved by a CAR-T treatment in early clinical trial.

Gene Therapy 52

Gene Therapy Production Development Business Development 52